How do you manage enthesitis? Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). https://t.co/BlC3onBYSX https://t.co/OXPdZuJHaN

Long-Term, open-label study enrolled EGPA (MIRRA study) required prednisolone ≥5 mg/d, pts cont mepolizumab 300 mg Sc q 4 wks +SOC. 100 pts - 71% completed, 3% d/C due to AEs. Exposure~38 mos; 38% serious AEs (30/100PYs) (worsening of asthma, EGPA https://t.co/GKxXN8p2Wz https://t.co/TFd9s3tfjK

Top 5 Clinical Pearls in RA Management #RNL2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in RA." https://t.co/DUalEZbfJB https://t.co/RZsW0SKc4J

Five Takeaways in PsA/SpA at RNL 2024 Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Click the link to read our five key takeaways and clinical pearls. https://t.co/ekKUl5WelF https://t.co/IdPXd7LR65

The ARIAA trial tested the utility of IV abatacept in individuals ACPA+ arthralgia patients with subclinical inflammation and showed abatacept to decrease MRI inflammation, clinical symptoms, and risk of future RA development. https://t.co/PdYLKwT0z9 https://t.co/O8uHxzleIK

Gabapentinoid use in COPD pts assoc w/ signif increased risk of severe exacerbation. Compared with nonuse, GABA use incr risk of COPD exacerbation when used for epilepsy (HR 1.58), neuropathic pain (HR 1.35), chronic pain (HR 1.49) https://t.co/EyONh9sASh https://t.co/Sr2FyJQzBj

Immune-Related Adverse Events of Immune Checkpoint Inhibitors - FULL READ overview in Annals of Internal Medicine. irAEs occur from few days to 1 year after ICI initiation; w/ 3-fold higher risk 1st 4 wks & only 7% starting 1 year after ICI https://t.co/jxEAl3rlCd https://t.co/IlmvV5kNfP

ACR 2023 Poster Available on RheumNow: JAKi Safety and Efficacy Through Week 204 in bDMARD-IR Patients with RA View long-term extension outcomes from the SELECT-CHOICE study in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs. https://t.co/3zEn9a2eml https://t.co/P7QXAmqJ2x

BC, Canada study of 149,902 new rheumatology referrals showed 31% more referrals 2019–2020 (vs 2010–2011). New inflammatory arthritis increased (28% to 51%), delays decr by 22 days; but time to 1st DMARD in RA decreased by only 4 days (6%) to 62 days https://t.co/LEyWcI6ojn https://t.co/QdL8VP1C6q

MMPs play pathogenic role in RA-ILD. Multicenter VA study of 2,312 RA pts, 96 had prevalent ILD & Incident ILD developed in 130 (IR 7.5/1,000PY). High MMP-7 increased ILD (adj OR 3.78) & incident ILD (adj HR 2.33). Higher MMP-9 did same https://t.co/W8IuDJCH8e https://t.co/UdiyyUt7jJ

UK Clinical Practice Research Datalink matched cohort study compared Gout (152K) to controls (709K) - CV devlopment higher in gout (21% vs 15%; HR 2.58). Moreso in women (HR 1.88). Gout pt had more CKD, HTN, obesity dyslipidaemia, & NIDDM https://t.co/BXCawnuIfa https://t.co/ZMuK9Msesb

2021 NHIS Survey data suggests the prevalence of immunosuppression in the USA is 6.6% (4.4% immunosuppressive Dz; 3.9% immunosuppressive meds; 1.8% both); higher in women 7.9% ages 60-69 (9.5%) & Alaskan/Native indian (8.4%) https://t.co/phFPRqpCbJ https://t.co/non7zpQVOL